Agios Pharmaceuticals Inc (NASDAQ:AGIO) Receives $71.00 Consensus Target Price from Brokerages
Shares of Agios Pharmaceuticals Inc (NASDAQ:AGIO) have received a consensus recommendation of “Hold” from the thirteen ratings firms that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation and six have given a buy recommendation to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $66.67.
AGIO has been the topic of a number of research analyst reports. BMO Capital Markets started coverage on shares of Agios Pharmaceuticals in a research note on Thursday. They issued an “outperform” rating and a $45.00 target price on the stock. BidaskClub cut shares of Agios Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, September 6th. Goldman Sachs Group restated a “neutral” rating and set a $55.00 price target on shares of Agios Pharmaceuticals in a research note on Thursday, May 23rd. Zacks Investment Research upgraded shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating and set a $46.00 price target on the stock in a research note on Wednesday, August 14th. Finally, Royal Bank of Canada set a $89.00 price target on shares of Agios Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, August 2nd.
Several hedge funds have recently made changes to their positions in AGIO. BlackRock Inc. lifted its stake in shares of Agios Pharmaceuticals by 30.8% during the 2nd quarter. BlackRock Inc. now owns 4,362,184 shares of the biopharmaceutical company’s stock valued at $217,585,000 after buying an additional 1,027,819 shares in the last quarter. Invesco Ltd. lifted its stake in shares of Agios Pharmaceuticals by 66.3% during the 2nd quarter. Invesco Ltd. now owns 1,396,773 shares of the biopharmaceutical company’s stock valued at $69,671,000 after buying an additional 556,825 shares in the last quarter. First Trust Advisors LP lifted its stake in Agios Pharmaceuticals by 31.4% in the 1st quarter. First Trust Advisors LP now owns 1,774,158 shares of the biopharmaceutical company’s stock worth $119,649,000 after purchasing an additional 423,931 shares in the last quarter. Westfield Capital Management Co. LP purchased a new stake in Agios Pharmaceuticals in the 1st quarter worth approximately $23,110,000. Finally, First Light Asset Management LLC purchased a new stake in Agios Pharmaceuticals in the 2nd quarter worth approximately $12,365,000.
Agios Pharmaceuticals (NASDAQ:AGIO) last released its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($1.87) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.70) by ($0.17). The company had revenue of $26.22 million during the quarter, compared to analysts’ expectations of $27.05 million. Agios Pharmaceuticals had a negative net margin of 383.05% and a negative return on equity of 59.89%. The firm’s revenue was down 35.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($1.19) earnings per share. On average, research analysts anticipate that Agios Pharmaceuticals will post -7.12 earnings per share for the current year.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next.
Read More: What is the cash asset ratio?
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.